Assembly Biosciences, Inc. (ASMB)

Market Cap	81.86M
Revenue (ttm)	6.25M
Net Income (ttm)	-126.61M
Shares Out	48.44M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,670
Open	1.66
Previous Close	1.66
Day's Range	1.66 - 1.76
52-Week Range	1.32 - 3.43
Beta	0.72
Analysts	Buy
Price Target	9.08 (+437.3%)
Earnings Date	Nov 2, 2022

About ASMB

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutu...

• Industry: Biotechnology
• IPO Date: Dec 17, 2010
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: ASMB

Full Company Profile

Financial Performance

In 2021, ASMB's revenue was $6.25 million, a decrease of -92.09% compared to the previous year's $79.11 million. Losses were -$129.86 million, 108.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is 9.08, which is an increase of 437.28% from the latest price.

Price Target

$9.08

(437.28% upside)

Analyst Consensus: Buy

Stock Forecasts